Research reveals promising novel strategy to target cancer-causing protein VIB … – EurekAlert (press release)

Research reveals promising novel strategy to target cancer-causing protein VIB …EurekAlert (press release)The team has also found that the mechanism can be interfered with antisense oligonucleotides (ASOs) to suppress cancer growth. The study which paves the way for the development of novel cancer therapeutics was published in the leading Journal of …and more »

Read More

Biogen initiates early-stage study of second-generation antisense drug in ALS – Seeking Alpha

Smarter AnalystBiogen initiates early-stage study of second-generation antisense drug in ALSSeeking AlphaIsis Pharmaceuticals (ISIS -3%) announces that alliance partner Biogen (BIIB -1.1%) has commenced a Phase 1/2 clinical trial evaluating ISIS-SODrx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). ISIS-SOD1rx is a Gen. 2.0+ antisense drug …Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS …PR Newswire (press release)Isis Pharma says Biogen starts phase 1/2 study of ISIS-SOD1 Rx in patients …Proactive Investors USA & Canadaall 6 news articles »

Read More

Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in … – Nature.com

Nature.comSelf-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in …Nature.comThe dual-colour RNA triple helix was constructed using three strands of RNA oligonucleotides, denoted as miR-205 sense, antisense and antagomiR-221 (RNA oligomers sequences are depicted in Supplementary Table 1). The miR-205 sense comprises a …Shrinking tumors with an RNA triple-helix hydrogel glue Brigham and Women’s …EurekAlert (press release)all 6 news articles »

Read More

December 4, 2015 | Isis Pharmaceuticals (NASDAQ:ISIS) Moves On Wells Fargo … – Independent Reporter

December 4, 2015 | Isis Pharmaceuticals (NASDAQ:ISIS) Moves On Wells Fargo …Independent ReporterThe Firm is focused to discover and develop antisense drugs. It has 522.05 P/E ratio. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer.Weekly Research Analysts’ Ratings Changes for ISIS Pharmaceuticals (ISIS)Dakota Financial NewsISIS Pharm (ISIS) is Initiated by Wells Fargo to OutperformMoney Flow IndexISIS Pharmaceuticals, Inc. (ISIS) Receives New Coverage from Analysts at Wells …Storm Investorall 11 news articles »

Read More

Patrick R. O’neil Sells 1000 Shares of ISIS Pharmaceuticals, Inc. (ISIS) Stock – Dakota Financial News

Patrick R. O’neil Sells 1000 Shares of ISIS Pharmaceuticals, Inc. (ISIS) StockDakota Financial NewsThe Company is focused to discover and develop antisense drugs. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer. ISIS-APOCIII is a …and more »

Read More

Cellmid granted midkine patent – NT News

Cellmid granted midkine patentNT NewsTHE patent is a part of its inhibitor patent portfolio and includes MK antibodies, antisense RNA and dsRNA against MK. The patent forms the basis for the commercial development of its MK antibodies in autoimmune disease indications. Increase Text Size …and more »

Read More

Research reveals MECP2 Duplication Syndrome can be reversed

The methyl CpG binding protein 2 gene (MECP2) produces a protein of the same name, the level of which is critical for normal brain function. Mutations leading to protein under-expression cause Rett Syndrome while gene duplication causing over-expression lead to MECP2 Duplication Syndrome. Both disorders are severely debilitating childhood neurological diseases.

Read More

MECP2 duplication syndrome is reversible – EurekAlert (press release)

MECP2 duplication syndrome is reversibleEurekAlert (press release)Importantly the study paves the way for treating duplication patients with an antisense oligonucleotide strategy. The research, funded in part by the MECP2 Duplication Syndrome Fund at the Rett Syndrome Research Trust (RSRT), was made possible through …Normalizing levels of MeCP2 in mouse model of MECP2 duplication syndrome …Medical Xpressall 6 news articles »

Read More

Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules … – FierceBiotech

Boston Business JournalIdera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules …FierceBiotechThis collaboration broadens the utility of our third generation antisense platform beyond the stated areas of focus for Idera in cancers and rare diseases,” stated Clayton Fletcher, Idera’s Senior Vice President of Business Development and Strategic …GSK, Idera Partner on Third-Gen Antisense Drugs for Renal DiseaseGenetic Engineering & Biotechnology News (blog)all 20 news articles »

Read More

GSK, Idera Partner on Third-Gen Antisense Drugs for Renal Disease – Genetic Engineering & Biotechnology News (blog)

Boston Business JournalGSK, Idera Partner on Third-Gen Antisense Drugs for Renal DiseaseGenetic Engineering & Biotechnology News (blog)GlaxoSmithKline (GSK) will partner with Idera Pharmaceuticals to research, develop and commercialize selected molecules from Idera’s third-generation antisense platform against targets in renal disease. The deal, announced today by Idera, could …Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules …FierceBiotechIdera Pharma (IDRA), Glaxo (GSK) Enter Antisense Development, License AgreementStreetInsider.comall 26 news articles »

Read More

Insider Sale: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)’s SVP – Antisense … – OctaFinance.com

STORMInsider Sale: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)’s SVP – Antisense …OctaFinance.comThe SVP – Antisense Research of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) 62.77 +0.73 1.18% and corporation’s insider Frank Bennett unloaded 5,000 shares of the -listed Isis Pharmaceuticals Inc based on the stock price per share of $64.0 of a share.Joseph Klein Unloaded $441234 Worth of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS …FinancialMagazin.comInsider Selling: C Frank Bennett Sells 5000 Shares of ISIS Pharmaceuticals …Voice ChronicleISIS Pharmaceuticals Director Joseph Klein III Sells 6875 Shares (ISIS)Dakota Financial NewsMidSouth Newz -STORMall 13 news articles »

Read More